Announcements Trials
Browse Landscape

Status

Completed 39Recruiting 23Unknown 13Terminated 7Active not recruiting 6Withdrawn 5Not yet recruiting 4Enrolling by invitation 4No longer available 3Available 1Approved for marketing 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Prostatic Neoplasms 5Recurrence 2Neoplasms 2Liver Neoplasms 2Lambert-Eaton Myasthenic Syndrome 2Carcinoma, Hepatocellular 2Wounds and Injuries 1Renal Insufficiency 1Prostatic Diseases 1Pheochromocytoma 1Paraganglioma 1Pancreatic Neoplasms 1Osteosarcoma 1Myasthenic Syndromes, Congenital 1Lymphoma 1Leukemia, Promyelocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia 1Congenital Abnormalities 1Colonic Neoplasms 1

Interventions

3-Iodobenzylguanidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Approved for marketing × OTHER × Pheochromocytoma × Clear all
NCT01377532 2020-05-06

Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma

University of California, San Francisco

Approved for marketing
CNSEndocrine

Neoplasms, Paraganglioma, Pheochromocytoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡